Ann: Commercial Partnership with Mobvoi for New Health Smartwatch, page-75

My reasons to invest in Cardiex.

✅ Gold standard FDA-cleared device for the measurement of central blood pressure and cardiovascular risk parameters (Standard FDA “predicate device”)
✅ Its currently used in 6 continents, 34 countries, 4000 plus installations
✅ 16 New Trademarks
✅ FDA and CFDA Approved
✅ Already obtained US reimbursement CPT Code
✅ All “Top 20 Hospitals” use SphygmoCor® technology to measure central blood pressure (cBP)
✅ 8 out of Top 10 Pharma companies have used SphygmoCor® technology in their clinical trials
✅ Over 11,000 patients have been tested with SphygmoCor® technology in pharmaceutical trials
✅ Disrupting a 100 year old health sector
✅ One of the most undervalued stock on ASX
✅ Huge potential with massive target market
✅ Exposure to US healthcare markets
✅ ‬Deep into the US telehealth sector worked with the biggest players such as Anthem (NSYE: ANTM)
‬✅ Showing leadership in the exciting and massive world of future health care
‬✅ Making strides in the US and now in China
‬✅ Right sector and management
✅ Current IP and technology focused on cardiovascular health
✅ Significant trademarks in consumer and wearable sectors
✅ Future applications in “Quantified Athlete”, remote patient monitoring, and broad health categories
✅ Proprietary IP & technology in cardiac load, athletic capacity, arterial stiffness, arterial age, and other consumer health diagnostic parameters
✅ Expanding licensing and co-development opportunities in broad medical and consumer health segments
✅ Over 1400 published peer-reviewed studies
✅ 13 USA patents covering significant applications in cardiovascular health and consumer wearables
✅ Launch of new devices and associated software/ digital solutions coming into the market in 2020 & 21 with a great CEO at the helm with novel products in a new and exciting space.
✅ Cutting edge technology products in the R&D development pipeline
✅ Share price doing well with increased volume
✅ Well funded now after the recent cap raise ( No discount and was investor lead)
✅ When combined with a current cash balance, the company is well funded to achieve its current milestones related to wearable technologies and new medical device developments

Valuation based on MST Access Research

Target Market

• “The medical/home-use market is forecast to be worth $US2.5bn in 2025 by Fortune Business Insights.”
• “Medical and consumer wearables is seen to touch $US37bn by 2025, by Industry Stats Report, which CardieX is accessing via partnerships with industry luminaries like Blumio and Mobvoi for a smartwatch.”
• “And finally, there’s the software-as-a-service (SaaS) opportunity, forecast at $US509bn by Grand View Research and including the company’s ARTY cloud-based digital hub, clinician portal and consumer app.”

New Product Development in 2020 and 2021


Market Comparable (My favorite slide)

Goals in 2020 and 2021


Timeline and Potential News flow


All in my opinion and research. Good luck to all.